Replies to post #106398 on Biotech Values

[DewDiligence]

IDIX—Given we are still two weeks away from the start of the AASLD conference, I'm more inclined to think that some investors felt the "intrinsic value" of the company as a whole depreciated too much since the FDA hold and have been accumulating for a while.

Let’s not kid ourselves into thinking that the FDA hold is a mere bump in the road. From the way JP Sommadossi has been talking on the most recent webcasts, it sounds as though IDX320 is likely dead, which means IDIX will not have an entrant in the PI class to offer to prospective partners.* This doesn’t mean IDIX can’t be a player in the all-oral HCV arena, but it does mean that there are fewer avenues for success.

*I presume that IDIX does not plan to resurrect the older PI’s, IDX136 and IDX316.